ID   ECC3
AC   CVCL_A1VE
SY   ICC15
DR   cancercelllines; CVCL_A1VE
DR   Cell_Model_Passport; SIDM01977
DR   DepMap; ACH-001841
DR   Wikidata; Q105509597
RX   PubMed=31109923;
RX   PubMed=39026794;
CC   Part of: Biliary tract cancer cell line atlas.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Sequence variation: Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Asn1718His (c.5152A>C); Zygosity=Unspecified (DepMap=ACH-001841).
CC   Sequence variation: Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Trp2788Ter (c.8363G>A); ClinVar=VCV000052564; Zygosity=Unspecified (DepMap=ACH-001841).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Cys141Tyr (c.422G>A); ClinVar=VCV000140801; Zygosity=Unspecified (DepMap=ACH-001841).
ST   Source(s): DepMap=ACH-001841
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 13
ST   D16S539: 10,12
ST   D18S51: 18
ST   D21S11: 31.2,32.2
ST   D3S1358: 17,18
ST   D5S818: 13
ST   D7S820: 11
ST   D8S1179: 10,14
ST   FGA: 24,25
ST   Penta D: 13
ST   Penta E: 13
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C4436; Cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 19-12-24; Version: 7
//
RX   PubMed=31109923; DOI=10.1158/2159-8290.CD-19-0182; PMCID=PMC6677584;
RA   Goyal L., Shi L., Liu L.Y., Fece de la Cruz F., Lennerz J.K.,
RA   Raghavan S., Leschiner I., Elagina L., Siravegna G., Ng R.W.S., Vu P.,
RA   Patra K.C., Saha S.K., Uppot R.N., Arellano R.S., Reyes S., Sagara T.,
RA   Otsuki S., Nadres B., Shahzade H.A., Dey-Guha I., Fetter I.J., Baiev I.,
RA   Van Seventer E.E., Murphy J.E., Ferrone C.R., Tanabe K.K., Deshpande V.,
RA   Harding J.J., Yaeger R.D., Kelley R.K., Bardelli A., Iafrate A.J.,
RA   Hahn W.C., Benes C.H., Ting D.T., Hirai H., Getz G., Juric D.,
RA   Zhu A.X.-X., Corcoran R.B., Bardeesy N.M.;
RT   "TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in
RT   patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma.";
RL   Cancer Discov. 9:1064-1079(2019).
//
RX   PubMed=39026794; DOI=10.1101/2024.07.04.601970; PMCID=PMC11257448;
RA   Vijay V., Karisani N., Shi L., Hung Y.-H., Vu P., Kattel P., Kenney L.,
RA   Merritt J., Adil R., Wu Q.-B., Zhen Y.-L., Morris R., Kreuzer J.,
RA   Kathiresan M., Herrera Lopez X.I., Ellis H., Gritti I.G., Lecorgne L.,
RA   Farag I., Popa A., Shen W., Kato H., Xu Q., Balasooriya E.R., Wu M.-J.,
RA   Chaturantabut S., Kelley R.K., Cleary J.M., Lawrence M.S., Root D.E.,
RA   Benes C.H., Deshpande V., Juric D., Sellers W.R., Ferrone C.R., Haas W.,
RA   Vazquez F., Getz G., Bardeesy N.M.;
RT   "Generation of a biliary tract cancer cell line atlas reveals
RT   molecular subtypes and therapeutic targets.";
RL   bioRxiv 2024:07.04.601970-07.04.601970(2024).
//